iBio, Inc. (IBIO)
Last updated: 2026-10-21 23:52:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
iBio, Inc. (IBIO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.84, with a market capitalization of $48.88M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.73 to $3.82. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$48.88M | |
$0.84 | |
$30,300.00 | |
$0.56 | |
$0.82 | |
506.58K | |
753.75K | |
-- | |
$3.82 | |
$0.73 | |
-- | |
-- |
iBio, Inc. (IBIO) After-Hours Stock Price
iBio, Inc. (IBIO) is trading at $0.87 in after-hours trading as of 2026-10-21 23:31:00, up 6.46% ($0.05) from the regular-session close of $0.82.
After-hours trading shows how investors are pricing IBIO after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
iBio, Inc. (IBIO) 7-Day Stock Price Change
Over the past seven days, iBio, Inc. (IBIO) moved from $0.90 to $0.84, representing a decline of 7.00% ($0.06).
The stock traded between $0.73 and $0.95 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 925.98 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
IBIO 52-Week Price Position
Position in Range: 3.5%
IBIO is currently trading at $0.84, placing it 3.5% of the way from its 52-week low of $0.73 to its 52-week high of $3.82. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is iBio, Inc. (IBIO)?
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.
iBio, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 23 |
| Exchange | NASDAQ |
| Company Website |
How to Buy iBio, Inc. (IBIO) Stock on MEXC
Eligible investors can buy real shares of iBio, Inc. (IBIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is iBio, Inc. (IBIO) stock price today?
2.Is IBIO stock going up or down today?
3.What is IBIO pre-market price?
4.What is IBIO after-hours price?
5.Is IBIO stock trading now?
6.Where does IBIO sit relative to its 52-week high and low?
7.What sector is iBio, Inc. in?
8.What is iBio, Inc.'s market capitalization and where is it listed?
9.How is IBIO valued in terms of P/E ratio and EPS?
10.Does iBio, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
IBIO Stock Calculator
Estimate the value between IBIO shares and USD.
IBIO Shares to USD
1.00 IBIO shares = 0.84 USD
Calculations are estimates based on the latest available price and are for reference only.


